RTP Mobile Logo
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Triple-Negative Breast Cancer (Webinar Video Proceedings)
Released January 2022

Featuring perspectives from Drs Sara Hurvitz, Rita Nanda and Melinda Telli, moderated by Dr Hope Rugo. Published January 7, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.


    • Review available research data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for newly diagnosed PD-L1-positive triple-negative breast cancer (TNBC), and use this information to identify patients who may be appropriate for this approach.
    • Evaluate published research findings, clinical factors (eg, age, performance status, prior therapeutic exposure) and patient preferences in the selection and sequencing of available therapeutic agents for patients with PD-L1-negative TNBC or those who experience disease progression on front-line chemoimmunotherapy.
    • Consider available research data supporting the recent FDA approval of immune checkpoint inhibitor therapy in the neoadjuvant and adjuvant settings for patients with localized TNBC, and reflect on the current role of this strategy in clinical practice.
    • Appraise published efficacy and safety data with PARP inhibitors for patients with metastatic breast cancer harboring BRCA1/2 mutations, and consider the diagnostic and therapeutic implications for nonresearch care.
    • Appreciate available Phase III data documenting the efficacy of adjuvant PARP inhibition for patients with high-risk, HER2-negative localized breast cancer with BRCA mutations, and consider the potential future role of this strategy in clinical practice.
    • Understand the FDA-approved indication for sacituzumab govitecan, and optimally incorporate this novel therapy into current treatment algorithms for patients with relapsed/refractory TNBC.
    • Analyze the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for TNBC.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SABCS2021/TNBC/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY & MODERATOR — The following faculty and moderator reported relevant financial relationships with ineligible entities:


    Sara Hurvitz, MD
    Professor of Medicine
    David Geffen School of Medicine at UCLA
    Director, Breast Cancer Clinical Research Program
    Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
    Santa Monica, California

    Contracted Research Paid to Institution: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, CytomX Therapeutics, Daiichi Sankyo Inc, Dignitana AB, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Immunomedics Inc, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Sanofi Genzyme, Seagen Inc, Zymeworks Inc.

    Rita Nanda, MD
    Director, Breast Oncology
    Associate Professor of Medicine
    Section of Hematology/Oncology
    The University of Chicago
    Chicago, Illinois

    Advisory Committee: Cardinal Health, Clovis Oncology, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, iTeos Therapeutics, MacroGenics Inc, Merck, OncoSec Medical, Pfizer Inc, Seagen Inc; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Corcept Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Merck, OBI Pharma Inc, Odonate Therapeutics, OncoSec Medical, Pfizer Inc, Seagen Inc, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: G1 Therapeutics Inc.

    Melinda Telli, MD
    Associate Professor of Medicine
    Stanford University School of Medicine
    Director, Breast Cancer Program
    Stanford Cancer Institute
    Stanford, California

    Advisory Committee: AbbVie Inc, Aduro Biotech, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Celgene Corporation, Daiichi Sankyo Inc, G1 Therapeutics Inc, Immunomedics Inc, Lilly, Natera Inc, Novartis, OncoSec Medical, Pfizer Inc, Sanofi Genzyme; Consulting Agreements: Genentech, a member of the Roche Group, Guardant Health, Merck; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biothera Pharmaceuticals Inc, Calithera Biosciences, EMD Serono Inc, Genentech, a member of the Roche Group, Merck, OncoSec Medical, Pfizer Inc, PharmaMar, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: G1 Therapeutics Inc, Immunomedics Inc.


    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Consulting Agreement: Samsung Bioepis (limited consulting); Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seagen Inc, Sermonix Pharmaceuticals; Honoraria: Mylan, Puma Biotechnology Inc; Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, MacroGenics Inc, Merck, Mylan, Novartis, Pfizer Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc and Merck.

    Release date: January 2022
    Expiration date: January 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):